Skip to Content
Is your RA under control? Take an assessment here >

Probenecid Pregnancy and Breastfeeding Warnings

Probenecid is also known as: Benemid

Probenecid Pregnancy Warnings

Benefit should outweigh risk AU TGA pregnancy category: B2 US FDA pregnancy category: B

This drug crosses the placental barrier and appears in cord blood. Case reports of use throughout pregnancy for the treatment of hyperuricemia associated with gout and renal dysfunction have not documented drug-induced adverse fetal outcomes. In addition, one study evaluating the efficacy of single-dose ampicillin plus probenecid for the treatment of urinary tract infection during pregnancy failed to reveal evidence of adverse fetal effects. There are no adequate and well controlled studies in pregnant women. AU TGA pregnancy category B2: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals are inadequate or may be lacking, but available data show no evidence of an increased occurrence of fetal damage. US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

See references

Probenecid Breastfeeding Warnings

Limited data has shown maternal doses of up to 2 g/day have resulted in low levels excreted into human milk. In animal studies, this drug has increased breastmilk excretion of cimetidine, possibly via an interaction with an active transport mechanism in the breast. The implications of enhanced excretion of drugs given with this drug have not been studied, however, only a few drugs are known to undergo active transport into breast milk. For infants older than 2 months, this drug is not expected to cause adverse effects.

Caution is recommended. Excreted into human milk: Yes

See references

References for pregnancy information

  1. "Product Information. Probenecid (probenecid)." Marlex Pharmaceuticals, New Castle, DE.
  2. Adelson MD, Graves WL, Osborne NG "Treatment of urinary infections in pregnancy using single versus 10-day dosing." J Natl Med Assoc 84 (1992): 73-5
  3. Cerner Multum, Inc. "Australian Product Information." O 0

References for breastfeeding information

  1. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Probenecid (probenecid)." Marlex Pharmaceuticals, New Castle, DE.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.